Quad-Modal Nutrition Matrix for Gut Health and Sustained Everyday Energy During GLP-1 Therapy

Overview

GLP-1 therapy can reduce food intake by a third or more, which often leads to inadequate protein, micronutrients, fluids, and energy. It can also slow gut motility, causing fatigue, constipation, and dehydration. This offering is a compact, non-stimulant nutritional matrix designed to address those side effects in a single 60–250 mL serving.

The matrix combines four complementary elements: amylase-resistant starch for slow colonic energy; a proprietary transporter-inducing amino acid blend; proprietary plant actives identified from a >2,000-candidate screen; and 100% RDA micronutrients with electrolytes. The plant actives are aromatic food-grade materials, which helps mask the taste of amino acids and minerals—enabling extreme nutrient density in a small volume.

The intended applications include a sachet, a 60–100 mL shot, and a milk additive format. It is designed for people on GLP-1 therapy who need to preserve muscle, maintain energy, normalize bowel function, and stay hydrated without stimulants or added glucose.

Technical specifications

Key mechanisms:

• Amylase-resistant starch escapes small-bowel digestion and ferments in the colon to short-chain fatty acids (butyrate, propionate, acetate), providing non-stimulant mitochondrial ATP, supporting tight-junction integrity, and promoting SCFA-coupled sodium and water uptake.
• The proprietary amino acid blend induces key intestinal transporters, including DMT1, NHE3, and SGLT1. In preclinical studies, DMT1 induction was approximately 1.5×, with iron flux increased up to 4× in Ussing chambers and ~2× in vivo.
• Proprietary plant actives from a >2,000-candidate screen are intended to restore enteric slow-wave peristalsis, inhibit nutrient- and glucose-driven crypt chloride secretion for net hydration, and expand transepithelial electrical resistance (TEER) and villus area.
• 100% RDA micronutrients plus electrolytes support repletion at reduced doses; the composition is designed to achieve a repletion potential (RP) of ≥2.0 at ≤50% of standard doses.

Target product formats: sachet (15–20 g), shot (60–100 mL), and milk additive (10–15 g).

Technology readiness level

The integrated composition is currently at TRL 3. A 36-month, four-stage validation plan is proposed to advance it to TRL 6.

Stage 1 will evaluate compatibility with GLP-1 therapy using Ussing chamber TEER and sodium/chloride flux measurements. Stage 2 will assess slow-wave normalization, tight-junction proteins, and villus growth, and will produce prototypes. Stage 3 will include GLP-1 rodent transit studies, dose-sparing micronutrient repletion studies, microbiome and SCFA analysis, and a generally recognized as safe (GRAS) dossier. Stage 4 will cover pilot manufacture in three formats and a human pilot study in approximately 40–60 participants, with endpoints including product liking, 4-week adherence, gastrointestinal comfort, and fatigue/vitality.

The organization leads transport, motility, rodent, IP, and clinical work; a co-development partner is sought for matrix/sensory optimization, stability, manufacture, and scale-up.